Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893688 | 1.00 | MAPT (0.68) | MAPTPKMPOLBALDH1A1LMNA | |
| Piperazine SCHEMBL28102264 | 0.98 | MAPT (0.66) | MAPTPKMPOLBALDH1A1LMNA | |
| SCHEMBL15284182 | 0.98 | MAPT (0.66) | MAPTPKMPOLBALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL16186 | 0.98 | MAPT (0.66) | MAPTPKMPOLBALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8130433 | 0.96 | MAPT (0.64) | MAPTPKMPOLBALDH1A1LMNA | |
| SCHEMBL6973412 | 0.93 | ALDH1A1 (0.60) | MAPTPKMPOLBALDH1A1LMNA | |
| SCHEMBL4225535 | 0.89 | ALDH1A1 (0.72) | MAPTPKMPOLBALDH1A1CYP2C9 | |
| SCHEMBL28897265 | 0.89 | ALDH1A1 (0.64) | MAPTPKMPOLBALDH1A1LMNA | |
| Trifluoroacetic Acid SCHEMBL7430837 | 0.87 | ALDH1A1 (0.55) | MAPTPKMPOLBALDH1A1HTR6 | |
| SCHEMBL3830424 | 0.85 | POLB (0.80) | PKMPOLBALDH1A1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-115521272-B | Benzenesulfonyl piperazine compound and medical application thereof | 河北省人民医院 | 2023-07-21 | — | — | CN | claimed |
| CN-111908822-B | Slump-retaining concrete synergist and preparation method thereof | 浙江鑫月新材料科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-115521272-A | Benzenesulfonyl piperazine compound and medical application thereof | 河北省人民医院 | 2022-12-27 | — | — | CN | claimed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | claimed |
| CN-114920704-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-08-19 | — | — | CN | claimed |
| CN-112300082-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-04-26 | — | — | CN | claimed |
| CN-112592114-A | Waterproof and antirust material for PC (polycarbonate) component | 浙江波威新材料科技有限公司 | 2021-04-02 | — | — | CN | claimed |
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | claimed |
| CN-111908822-A | Slump-retaining concrete synergist and preparation method thereof | 浙江鑫美博新材料有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-109824756-A | Contain 4-(benzenesulfonyl) phenylalanine derivative and the preparation method and application thereof of piperazine -2- ketone | 山东大学 | 2019-05-31 | — | — | CN | claimed |
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | claimed |
| EP-2850068-A1 | GPR17 RECEPTOR MODULATORS. | Universita' degli Studi di Milano (IT) | 2015-03-25 | — | — | EP | claimed |
| CN-101870699-B | Benzenesulfonyl piperazine derivative and preparation method thereof | QI YOUMAO | 2013-11-20 | — | — | CN | claimed |
| WO-2013167177-A1 | GPR17 RECEPTOR MODULATORS. | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2013-11-14 | — | — | WO | claimed |
| CN-101870699-A | Benzenesulfonyl piperazine derivative and preparation method thereof | YOUMAO QI | 2010-10-27 | — | — | CN | claimed |
| US-20100240800-A1 | BIOCIDAL ELASTOMERIC COMPOSITIONS AND METHODS OF MAKING THE SAME | DASH MULTI-CORP (US) | 2010-09-23 | — | — | US | claimed |
| EP-1054887-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2000-11-29 | — | — | EP | claimed |
| WO-1999040091-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 1999-08-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141410-A1 | GPR17 Receptor Modulators | GPR65, GPR27, GPR17 | MAPT 1710/4885PKM 3338/4885POLB 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.